Search Results

Business

OpGen’s Subsidiary Curetis and FIND Extend R&D Collaboration Agreement

OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported that its German subsidiary Curetis GmbH has signed an extended and continued research and development collaboration agreement with FIND.

August 3, 2023

·

6 min read

Business

OpGen’s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND

OpGen, Inc. reported today that its German subsidiary Curetis GmbH has met all milestones under its extended and expanded research and development (“R&D”) collaboration agreement with FIND.

July 19, 2023

·

5 min read

BioCapital

OpGen’s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments

OpGen, Inc. reported that its German subsidiary, Curetis GmbH, has received the full set of ten Unyvero A30 C-Series instruments, which have been assembled by its development partner, DMTPe, in Germany.

June 22, 2023

·

4 min read

BioCapital

OpGen’s Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND

OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported that its German subsidiary Curetis GmbH has met the remaining key milestones under the initial research and development collaboration agreement with FIND.

April 26, 2023

·

4 min read

BioCapital

OpGen’s Subsidiary Curetis and European Investment Bank Plan to Restructure Debt Repayment

OpGen, Inc. announced that its subsidiary, Curetis GmbH, and the European Investment Bank expect to restructure the repayment of the first tranche which matured on April 22, 2022.

April 25, 2022

·

5 min read

Business

OpGen Subsidiary Curetis and Leader Life Sciences Enter into Unyvero Distribution Partnership for U.A.E. and Qatar

OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that its subsidiary Curetis GmbH has entered into a distribution agreement with Leader Life Sciences.

June 9, 2022

·

5 min read

BioCapital

OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND

OpGen, Inc. reported that it signed an amendment to its research and development collaboration agreement with FIND, to expand the collaboration which was originally started in fall of 2022.

April 5, 2023

·

4 min read

Business

OpGen’s Subsidiary Curetis Meets Milestones in Collaborative Research Project with InfectoGnostics

OpGen, Inc. reported that it has completed two interim milestones as part of its collaboration project with InfectoGnostics under the PREPLEX grant.

April 3, 2023

·

5 min read

Business

OpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration Project

OpGen, Inc. today announced that the Company has received confirmation from FIND, the global alliance for diagnostics, that several key milestones under its collaboration agreement with the global non-profit organization have been successfully met as of the end of 2022.

January 17, 2023

·

5 min read

Business

OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support

OpGen, Inc. and BioVersys AG today announced the signing of a collaboration agreement for the deployment and use of the Unyvero platform in BioVersys’ upcoming Phase II clinical trial of novel drug candidate BV100.

October 25, 2022

·

6 min read